ClinicalTrials.gg
Active, not recruitingNCT05816252Updated Nov 9, 2026

A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)

A Phase 2 interventional study of SKB264 and Pembrolizumab in Non-small Cell Lung Cancer, sponsored by Klus Pharma Inc.. Active, not recruiting at 50 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Klus Pharma Inc. · Phase 2, Interventional, and Treatment

Updated Nov 9, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
356
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing sacituzumab tirumotecan in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 26 under way, 9 of them phase 3. sacituzumab tirumotecan · Carcinoma, Non-Small-Cell Lung.

Enrollment
11th of 26
356 · median 115
Started
2023
with 4 others
Phase 2
15 of 26
13 open now
Primary completion
2026-08
later than 4 of 25 live
Registered
3rd of 26
by date
Lead sponsor
2 of 26
Klus Pharma Inc.

Among the 26 studies testing sacituzumab tirumotecan in Carcinoma, Non-Small-Cell Lung, this one is the 11th largest by enrollment, is one of 5 that started in 2023, is one of 15 in phase 2, reaches primary completion later than 4 of the 25 other live ones, and was the 3rd registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 26 studies testing sacituzumab tirumotecan in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About sacituzumab tirumotecan

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing sacituzumab tirumotecan in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability and objective response rate of SKB264 as combination with therapy in subjects with advanced or metastatic non-small cell lung cancer.

Read the detailed description

This is a multicenter, open-label study of SKB264 as combination therapy or monotherapy in subjects with NSCLC. Approximately 498 subjects will be enrolled in this study including around 88 subjects for the safety run-in period and 410 subjects for the expansion period.

03

Conditions studied

  • Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must be at least 18 years of age on day of signing , regardless of gender;
  2. Subjects with or cytologically confirmed locally advanced or NSCLC ;
  3. Subjects for NSCLC should be confirmed to be EGFR (Epidermal growth factor receptor) wild-type and ALK (Anaplastic lymphoma kinase) fusion gene negative; or confirmed to harbor EGFR mutation;
  4. Locally advanced or metastatic NSCLC subjects without actionable EGFR mutations and ALK fusion genes, no prior systemic treatment; subjects with EGFR mutation, no prior systemic treatment or failed prior EGFR-TKI (Tyrosine kinase inhibitor) treatment;
  5. Subjects are able to provide tumor blocks or slides before the first dose of study intervention;
  6. Subject must have at least one radiographically as per (RECIST) v1.1 criteria;
  7. Subject has an (ECOG) performance status of either 0 or 1;
  8. at least 3 months for the subject;
  9. Adequate organ function;
  10. Subjects must have recovered from all toxicities led by prior treatment;
  11. methods used by male and female subjects must comply with contraceptive methods of local regulations for clinical study subjects;
  12. Subjects should voluntarily participate in the study, sign the ICF, and will be able to comply with the protocol-specified visits and relevant procedures.

Exclusion criteria

Exclusion Criteria

  1. Subjects with mixed SCLC histopathological features;
  2. Subjects with a known history of prior ;
  3. Subjects with known meningeal , brainstem metastases, spinal cord metastases and/or compression, or active central nervous system (CNS) metastases;
  4. Subjects with ≥ Grade 2 peripheral neuropathy;
  5. Subjects who had arteriovenous thromboembolic events, tumor invasion/encasement of vital organs/vessels, risk of esophageal-tracheal/pleural fistula, or current superior vena cava syndrome;
  6. Subjects with active inflammatory bowel disease or previous clear history of inflammatory bowel disease;
  7. Subjects who suffer from cardiovascular diseases of clinical significance;
  8. Subjects with a history of interstitial lung disease (ILD)/non-infectious pneumonitis that required ;
  9. Subjects with uncontrolled systemic disease as judged by the Investigator;
  10. Subjects with active disease that required systemic treatment in the past 2 years;
  11. Subjects with active or ;
  12. Subjects with known history of (HIV)
  13. Subjects with known active tuberculosis;
  14. Subjects with known history of allogeneic organ transplantation and hematopoietic stem cell transplantation;
  15. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study;
  16. Subjects whose condition deteriorated rapidly, such as severe changes in performance status, during the screening process prior to the first dose of study intervention;
  17. Subjects with other circumstances that, in the opinion of the Investigator, are not appropriate for participation in this study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
356 participants (actual)

Study arms

  • Experimental
    Cohort 1 1L NSCLC, EGFR/ALK negative and PD-L1 TPS ≥ 1%

    SKB264 (Dose Level 1) + Pembrolizumab

    Drug: SKB264 · Drug: Pembrolizumab

  • Experimental
    Cohort 3 1L NSCLC, EGFR/ALK negative, regardless of PD-L1 expression level

    SKB264 (Dose Level 1') + Pembrolizumab + Carboplatin

    Drug: SKB264 · Drug: Pembrolizumab · Drug: Carboplatin

  • Experimental
    Cohort 4 1L NSCLC, EGFR/ALK negative, regardless of PD-L1 expression level

    SKB264 (Dose Level 1'') + Pembrolizumab + Carboplatin

    Drug: SKB264 · Drug: Pembrolizumab · Drug: Carboplatin

  • Experimental
    Cohort 5 NSCLC with EGFR mutation and after failure of EGFR TKI therapy

    SKB264 (Dose Level 1') + Carboplatin

    Drug: SKB264 · Drug: Carboplatin

  • Experimental
    Cohort 6 NSCLC with EGFR mutation and after failure of EGFR TKI therapy

    SKB264 (Dose Level 1'') + Carboplatin

    Drug: SKB264 · Drug: Carboplatin

  • Experimental
    Cohort 7 1L NSCLC with EGFR mutation

    SKB264 (Dose Level 1) + Osimertinib

    Drug: SKB264 · Drug: Osimertinib

  • Experimental
    Cohort 7-1 1L NSCLC with EGFR mutation

    SKB264 (Dose Level 2) + Osimertinib

    Drug: SKB264 · Drug: Osimertinib

  • Experimental
    Cohort 9 2/3L NSCLC EGFR/ALK negative

    SKB264 (Dose Level 1)

    Drug: SKB264

Interventions

  • DrugSKB264

    intravenous (IV) infusion (Q2W or Q3W)

    Also known as: MK-2870, Sacituzumab Tirumotecan (Sac-TMT)

  • intravenous (IV) infusion (400mg, Q6W)

    Also known as: MK-3475

  • intravenous (IV) infusion (AUC5, Q3W)

    Also known as: Carboplatin for injection

  • 80mg, QD

    Also known as: Osimertinib Mesylate

06

What researchers measure

Primary outcomes

  1. Safety and tolerability

    Dose-limiting toxicity (DLT); Incidence and severity of adverse events (AEs); Discontinuation of study treatment due to AEs

    Time frame: From subject sign the informed consent form (ICF) to 30 days after the last dose of study treatment, up to approximately 36 months

  2. ORR

    Objective response rate (ORR) per RECIST v1.1

    Time frame: The proportion of subjects with a confirmed complete response (CR) or partial response (PR), up to approximately 36 months

Secondary outcomes

  1. Duration of response (DOR)

    For subjects with a confirmed CR or PR, DOR is defined as the time from the first documented evidence of CR or PR until radiographic disease progression or death due to any cause, whichever occurs first

    Time frame: From baseline until disease progression, death, or other protocol defined reason, up to approximately 36 months

  2. Progression-free survival (PFS)

    The time from first dose of study intervention to first documentation of radiographic disease progression or death due to any cause, whichever occurs first

    Time frame: From baseline until disease progression, death, or other protocol defined reason, up to approximately 36 months

  3. Overall survival (OS)

    the time period from the start of study intervention to death due to any cause.

    Time frame: From baseline until death due to any cause, up to approximately 36 months

07

Study locations

50 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Aug 2026, 40 months.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 40 months is close to that.

Counting every sponsor, half of 1,046 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Jun 2026 → Aug 2026 and completion Dec 2026 → Aug 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2023
First posted
Apr 18, 2023
StartActual
Apr 19, 2023
Primary completionActual
Aug 31, 2026was Jun 2026
CompletionEst.
Aug 31, 2028was Dec 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
13 sites added, 13 sites removed
Show 13 added (6 Spain, 4 Turkey (Türkiye), 3 Georgia)
  • ISR-GEO Med Res Clin Healthycore · Tbilisi, Georgia
  • LLC "Todua Clinic" · Tbilisi, Georgia
  • Ltd New Hospitals · Tbilisi, Georgia
  • Micancer Center S.L.P. · Barcelona, Spain
  • Hospital Universitari Dexeus Grupo Quironsalud · Barcelona, Spain
  • Hospital Universitari Vall D Hebron · Barcelona, Spain
  • Hospital Quironsalud Malaga · Málaga, Spain
  • Hospital Universitario Virgen de Valme · Seville, Spain
  • Hospital Clinico Universitario De Valencia · Valencia, Spain
  • Medical Park Seyhan Hospital · Adana, Turkey (Türkiye)
  • Adana City Training and Research Hospital · Adana, Turkey (Türkiye)
  • Gulhane Egitim ve Arastirma Hastanesi Tibbi Onkoloji Klinigi · Ankara, Turkey (Türkiye)
  • Hacettepe University Medical Faculty · Ankara, Turkey (Türkiye)
Show 13 removed
  • ISR-GEO Med Res Clin Healthycore · Tbilisi, Georgia
  • LLC "Todua Clinic" · Tbilisi, Georgia
  • Ltd New Hospitals · Tbilisi, Georgia
  • Micancer Center S.L.P. · Barcelona, Spain
  • Hospital Universitari Dexeus Grupo Quironsalud · Barcelona, Spain
  • Hospital Universitari Vall D Hebron · Barcelona, Spain
  • Hospital Quironsalud Malaga · Málaga, Spain
  • Hospital Universitario Virgen de Valme · Seville, Spain
  • Hospital Clinico Universitario De Valencia · Valencia, Spain
  • Medical Park Seyhan Hospital · Adana, Turkey (Türkiye)
  • Adana City Training and Research Hospital · Adana, Turkey (Türkiye)
  • Gulhane Egitim ve Arastirma Hastanesi Tibbi Onkoloji Klinigi · Ankara, Turkey (Türkiye)
  • Hacettepe University Medical Faculty · Ankara, Turkey (Türkiye)
Nov 9, 2026
Primary completion
Jun 30, 2026→Aug 31, 2026 (actual)
Nov 9, 2026
Study completion
Dec 30, 2026→Aug 31, 2028
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    13 sites added, 13 sites removed
    Show 13 added (6 Spain, 4 Turkey (Türkiye), 3 Georgia)
    • ISR-GEO Med Res Clin Healthycore · Tbilisi, Georgia
    • LLC "Todua Clinic" · Tbilisi, Georgia
    • Ltd New Hospitals · Tbilisi, Georgia
    • Micancer Center S.L.P. · Barcelona, Spain
    • Hospital Universitari Dexeus Grupo Quironsalud · Barcelona, Spain
    • Hospital Universitari Vall D Hebron · Barcelona, Spain
    • Hospital Quironsalud Malaga · Málaga, Spain
    • Hospital Universitario Virgen de Valme · Seville, Spain
    • Hospital Clinico Universitario De Valencia · Valencia, Spain
    • Medical Park Seyhan Hospital · Adana, Turkey (Türkiye)
    • Adana City Training and Research Hospital · Adana, Turkey (Türkiye)
    • Gulhane Egitim ve Arastirma Hastanesi Tibbi Onkoloji Klinigi · Ankara, Turkey (Türkiye)
    • Hacettepe University Medical Faculty · Ankara, Turkey (Türkiye)
    Show 13 removed
    • ISR-GEO Med Res Clin Healthycore · Tbilisi, Georgia
    • LLC "Todua Clinic" · Tbilisi, Georgia
    • Ltd New Hospitals · Tbilisi, Georgia
    • Micancer Center S.L.P. · Barcelona, Spain
    • Hospital Universitari Dexeus Grupo Quironsalud · Barcelona, Spain
    • Hospital Universitari Vall D Hebron · Barcelona, Spain
    • Hospital Quironsalud Malaga · Málaga, Spain
    • Hospital Universitario Virgen de Valme · Seville, Spain
    • Hospital Clinico Universitario De Valencia · Valencia, Spain
    • Medical Park Seyhan Hospital · Adana, Turkey (Türkiye)
    • Adana City Training and Research Hospital · Adana, Turkey (Türkiye)
    • Gulhane Egitim ve Arastirma Hastanesi Tibbi Onkoloji Klinigi · Ankara, Turkey (Türkiye)
    • Hacettepe University Medical Faculty · Ankara, Turkey (Türkiye)
    Primary completion Jun 30, 2026→Aug 31, 2026 (now actual)
    Study completion Dec 30, 2026→Aug 31, 2028
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05816252
Lead sponsor
Klus Pharma Inc.
Responsible party
Sponsor
First posted
Apr 18, 2023
Start date
Apr 19, 2023
Primary completion
Aug 31, 2026
Completion
Aug 31, 2028 (estimated)
Last update
Nov 9, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sacituzumab tirumotecan

Start the discussion